Does the media favor CRDL or CRVO?

In the previous week, CervoMed had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for CervoMed and 3 mentions for Cardiol Therapeutics. CervoMed's average media sentiment score of 1.28 beat Cardiol Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UNCY or CRVO?

In the previous week, CervoMed had 6 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Unicycive Therapeutics. CervoMed's average media sentiment score of 1.28 beat Unicycive Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or CRVO more profitable?

Oncobiologics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Oncobiologics' return on equity of 0.00% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% CervoMed -672.80% -166.00% -132.72%

Does the media favor OTLK or CRVO?

In the previous week, CervoMed had 6 more articles in the media than Oncobiologics. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Oncobiologics. CervoMed's average media sentiment score of 1.28 beat Oncobiologics' score of 0.50 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CUE or CRVO?

CervoMed has a consensus target price of $21.50, suggesting a potential upside of 651.75%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Is CUE or CRVO more profitable?

Cue Biopharma has a net margin of -59.65% compared to CervoMed's net margin of -672.80%. Cue Biopharma's return on equity of -98.30% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -59.65% -98.30% -53.69% CervoMed -672.80% -166.00% -132.72%

Does the media favor CUE or CRVO?

In the previous week, CervoMed had 6 more articles in the media than Cue Biopharma. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Cue Biopharma. CervoMed's average media sentiment score of 1.28 beat Cue Biopharma's score of 0.50 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRVO or HURA more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. TuHURA Biosciences' return on equity of -156.12% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -166.00% -132.72% TuHURA Biosciences N/A -156.12% -105.38%

Does the media refer more to CRVO or HURA?

In the previous week, CervoMed had 7 more articles in the media than TuHURA Biosciences. MarketBeat recorded 8 mentions for CervoMed and 1 mentions for TuHURA Biosciences. CervoMed's average media sentiment score of 1.28 beat TuHURA Biosciences' score of 0.00 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CervoMed (CRVO) Competitors

$2.86 -0.01 (-0.35%)

As of 04:00 PM Eastern

Compare

CRVO vs. CRDL, UNCY, OTLK, CUE, and HURA

Should you buy CervoMed stock or one of its competitors? MarketBeat compares CervoMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CervoMed include Cardiol Therapeutics (CRDL), Unicycive Therapeutics (UNCY), Oncobiologics (OTLK), Cue Biopharma (CUE), and TuHURA Biosciences (HURA).

How does CervoMed compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, CervoMed had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for CervoMed and 3 mentions for Cardiol Therapeutics. CervoMed's average media sentiment score of 1.28 beat Cardiol Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 478.23%. CervoMed has a consensus target price of $21.50, indicating a potential upside of 651.75%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Cardiol Therapeutics has higher earnings, but lower revenue than CervoMed. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -166.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
CervoMed	-672.80%	-166.00%	-132.72%

Summary

CervoMed beats Cardiol Therapeutics on 12 of the 16 factors compared between the two stocks.

How does CervoMed compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Unicycive Therapeutics has higher earnings, but lower revenue than CervoMed. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	202.20	-$26.56M	-$2.21	N/A
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Unicycive Therapeutics' return on equity of -134.69% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
CervoMed	-672.80%	-166.00%	-132.72%

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market.

Unicycive Therapeutics currently has a consensus price target of $21.75, indicating a potential upside of 333.27%. CervoMed has a consensus price target of $21.50, indicating a potential upside of 651.75%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CervoMed had 6 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Unicycive Therapeutics. CervoMed's average media sentiment score of 1.28 beat Unicycive Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Unicycive Therapeutics beats CervoMed on 9 of the 17 factors compared between the two stocks.

How does CervoMed compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Oncobiologics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Oncobiologics' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
CervoMed	-672.80%	-166.00%	-132.72%

CervoMed has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	126.58	-$62.42M	-$1.17	N/A
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A

Oncobiologics currently has a consensus price target of $4.65, suggesting a potential upside of 304.35%. CervoMed has a consensus price target of $21.50, suggesting a potential upside of 651.75%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 35.8% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CervoMed had 6 more articles in the media than Oncobiologics. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Oncobiologics. CervoMed's average media sentiment score of 1.28 beat Oncobiologics' score of 0.50 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, indicating that its stock price is 163% less volatile than the broader market.

Summary

CervoMed beats Oncobiologics on 12 of the 17 factors compared between the two stocks.

How does CervoMed compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, CervoMed had 6 more articles in the media than Cue Biopharma. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Cue Biopharma. CervoMed's average media sentiment score of 1.28 beat Cue Biopharma's score of 0.50 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed has a consensus target price of $21.50, suggesting a potential upside of 651.75%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Cue Biopharma has higher revenue and earnings than CervoMed. Cue Biopharma is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.99	-$26.60M	-$5.58	N/A
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A

Cue Biopharma has a net margin of -59.65% compared to CervoMed's net margin of -672.80%. Cue Biopharma's return on equity of -98.30% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
CervoMed	-672.80%	-166.00%	-132.72%

Cue Biopharma has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, indicating that its stock price is 163% less volatile than the broader market.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CervoMed beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.

How does CervoMed compare to TuHURA Biosciences?

CervoMed (NASDAQ:CRVO) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

CervoMed currently has a consensus price target of $21.50, suggesting a potential upside of 651.75%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 318.60%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, CervoMed had 7 more articles in the media than TuHURA Biosciences. MarketBeat recorded 8 mentions for CervoMed and 1 mentions for TuHURA Biosciences. CervoMed's average media sentiment score of 1.28 beat TuHURA Biosciences' score of 0.00 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

25.2% of CervoMed shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

CervoMed has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

TuHURA Biosciences has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. TuHURA Biosciences' return on equity of -156.12% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-166.00%	-132.72%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Summary

CervoMed beats TuHURA Biosciences on 10 of the 16 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.70M	$11.95B	$7.05B	$12.94B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.89	788.54	269.76	24.76
Price / Sales	9.65	966.07	651.81	108.50
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.45	10.35	11.28	6.42
Net Income	-$26.97M	$2.77B	$3.45B	$347.27M
7 Day Performance	10.00%	2.10%	3.61%	2.52%
1 Month Performance	-19.89%	-1.49%	-0.53%	-1.00%
1 Year Performance	-70.96%	191.34%	77.55%	23.29%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	3.8549 of 5 stars	$2.86 -0.3%	$21.50 +651.7%	-70.9%	$38.70M	$4.01M	N/A	4	News Coverage Positive News Earnings Report
CRDL Cardiol Therapeutics	2.242 of 5 stars	$1.20 +3.5%	$8.50 +611.3%	+44.0%	$137.72M	N/A	N/A	20	Upcoming Earnings
UNCY Unicycive Therapeutics	2.326 of 5 stars	$5.01 -2.4%	$21.75 +334.6%	+24.0%	$137.09M	$680K	N/A	9	Upcoming Earnings
OTLK Oncobiologics	3.9756 of 5 stars	$0.91 -14.9%	$4.65 +413.2%	-46.3%	$133.73M	$333.14K	N/A	20	Upcoming Earnings High Trading Volume
CUE Cue Biopharma	0.2645 of 5 stars	$31.91 -2.0%	N/A	-96.4%	$133.09M	$32.73M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. CRDL, UNCY, OTLK, CUE, and HURA

How does CervoMed compare to Cardiol Therapeutics?

Summary

How does CervoMed compare to Unicycive Therapeutics?

Summary

How does CervoMed compare to Oncobiologics?

Summary

How does CervoMed compare to Cue Biopharma?

Summary

How does CervoMed compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. CRDL, UNCY, OTLK, CUE, and HURA

How does CervoMed compare to Cardiol Therapeutics?

Does the media favor CRDL or CRVO?

Do analysts prefer CRDL or CRVO?

Which has preferable valuation & earnings, CRDL or CRVO?

Do institutionals and insiders hold more shares of CRDL or CRVO?

Which has more risk & volatility, CRDL or CRVO?

Is CRDL or CRVO more profitable?

Summary

How does CervoMed compare to Unicycive Therapeutics?

Which has better earnings & valuation, UNCY or CRVO?

Is UNCY or CRVO more profitable?

Which has more volatility & risk, UNCY or CRVO?

Do analysts prefer UNCY or CRVO?

Do insiders & institutionals have more ownership in UNCY or CRVO?

Does the media refer more to UNCY or CRVO?

Summary

How does CervoMed compare to Oncobiologics?

Is OTLK or CRVO more profitable?

Which has higher earnings and valuation, OTLK or CRVO?

Do analysts rate OTLK or CRVO?

Do institutionals & insiders believe in OTLK or CRVO?

Does the media favor OTLK or CRVO?

Which has more volatility & risk, OTLK or CRVO?

Summary

How does CervoMed compare to Cue Biopharma?

Does the media favor CUE or CRVO?

Do analysts rate CUE or CRVO?

Which has preferable valuation and earnings, CUE or CRVO?

Is CUE or CRVO more profitable?

Which has more risk and volatility, CUE or CRVO?

Do insiders & institutionals believe in CUE or CRVO?

Summary

How does CervoMed compare to TuHURA Biosciences?

Do analysts prefer CRVO or HURA?

Does the media refer more to CRVO or HURA?

Do institutionals & insiders hold more shares of CRVO or HURA?

Which has more risk and volatility, CRVO or HURA?

Which has higher valuation & earnings, CRVO or HURA?

Is CRVO or HURA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools